Clinical Trials
4 trialsNCT06374459 2026-04-20
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Washington University School of Medicine
Phase 1/2 Recruiting
NCT04549207 2026-04-07
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT04067726 2026-03-31
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting